Innovation Ventures

Contact Us
☰
  • Partnering Opportunities
  • Partners
  • Investors
  • Innovators
  • About
  • Subscribe
  • facebookyoutubetwitterpinterest
Allergy

Activation of Aryl Hydrocarbon Receptor (AHR) as a therapeutic for Eosinophilic Esophagitis (EoE).

Recent studies have linked the importance of AHR as a regulator of EoE pathogenesis and the potential of AHR activation by small molecules as EoE therapy.


Technology Overview

Currently, there are no US FDA-approved small molecule treatments for EoE. Available off-label standard of care treatments, including proton pump inhibitors and corticosteroids, do not show a response in up to half of EoE patients. SPINK7 is an epithelial serine protease inhibitor that is highly expressed in the esophagus and markedly decreased in patients with eosinophilic esophagitis (EoE).  Loss of SPINK7 in esophageal epithelial cells promotes barrier impairment and pro-inflammatory innate immune responses. Activation of AHR by delivery of AHR ligands increase the expression of SPINK7 as well as epithelial barrier and differentiation genes that are important for inducing the barrier function and preventing inflammatory pathways.  Blocking AHR with an AHR antagonist, inhibited AHR-ligand dependent SPINK7 expression. Activation of AHR induces a transcription program, including SPINK7 expression, and has been shown to be a novel therapeutic target for small molecule treatment of EoE.

Applications

  • Improved barrier function in EoE
  • Blocks epithelial immune response

Advantages

  • Novel small molecule therapeutic treatment of EoE

Market Overview

Estimated occurrences of EoE in pediatric and adult populations are 43–57 per 100,000 persons. More effective or curative treatments for EoE are a critical unmet need and the current US market is valued around $156 million with an expected growth to $1.9 Billion by 2030.

Investigator Overview

Nurit Azouz, PhD & Marc Rothenberg, MD, PhD, Division of Allergy & Immunology

Technology ID

2020-0806

Business Opportunity

Exclusive License or Sponsored Research

Technology Type

Small Molecule

Stage of Development

Pre-Clinical - In Vitro

Patent Information

PCT Filed


Download PDF


Contact Innovation Ventures

partnering@cchmc.org 1.513.636.4285

Cincinnati Children’s Innovation Ventures

3333 Burnet Avenue, MLC 7032 Cincinnati, Ohio 45229-3026 | partnering@cchmc.org

© 1999-2022 Cincinnati Children's Hospital Medical Center